Paris, France and Camberley, UK - 6th December 2018 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign's q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular diagnostic instruments has been paid in advance and takes the number of q16 instruments sold into the Asia Pacific region to over 230 units.
The genesig® q16 is Primerdesign's proprietary molecular testing instrument which is designed to make DNA testing affordable and easy to use. The latest order comes from a new distributor recently appointed by Novacyt and the instruments will be used in clinical diagnostic markets. This new customer provides Novacyt with a potential opportunity for further significant instrument, and genesig® reagent sales in 2019.
Primerdesign has now sold over 450 q16 units since its launch in 2015. As instrument sales grow, the Company expects a pull-through effect in relation to repeat genesig® reagent sales. Reflecting this, year to date genesig® reagent sales have increased 35% versus the comparable period in 2017.
Graham Mullis, Group CEO of Novacyt, commented:
"I am very pleased to see this order from another new customer in China which helps to further reinforce our continued investment and success in the Asia Pacific region and provides additional opportunities for future instrument and reagent sales".
|
Thread abonnieren
ETF-Sparplan